Today, Sanofi announced that for all babies, the long-lasting monoclonal antibody Lweechu (Niseweide monoclonal antibody injection) for respiratory syncytial virus (RSV) prevention has been officially launched for commercialization in China. The product's new drug marketing application was approved by the National Medical Products Administration in December 2023 and is the first innovative means approved for infant prevention of RSV-caused lower respiratory tract infections and currently the only one approved in China.
赛诺菲宣布乐唯初在中国正式商业化上市
Sanofi announced that Lweechu has officially launched for commercialization in China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.